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Adding insulin glargine vs. NPH insulin to metformin results
in a more efﬁcient postprandial β-cell protection in
individuals with type 2 diabetes
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Aim: Postprandial release of intact proinsulin (IP) is an independent marker for β-cell dysfunction in patients with type 2 diabetes. This
open-label, parallel-group, two-arm, pilot study compared the β-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing
metformin.
Material and methods: Overall, 28 insulin-naive type 2 diabetes subjects (mean ± SD age, 61.5 ± 6.7 years; diabetes duration, 9.8 ± 6.5
years; HbA1c, 7.1 ± 0.5%; BMI, 30.7 ± 4.3 kg/m2) treated with metformin and sulfonylurea were randomized to add once-daily GLA or NPH
at bedtime. At baseline and after 3 months, subjects received a standardized breakfast, lunch and dinner, with pre- and postprandial blood
sampling to measure plasma IP, total insulin and blood glucose (BG).
Results: Insulin dose after 3 months was comparab l ei nb o t hg r o u p s( G L Av s .N P H :2 3 . 6± 13.4 vs. 23.3 ± 12.7; p = NS). Both treatments
signiﬁcantly reduced fasting BG levels (GLA: 158 ± 19 to 121 ± 23 mg/dl; NPH: 156 ± 34 to 119 ± 29 mg/dl; both p < 0.01 vs. baseline).
Fasting and postprandial BG levels did not differ between groups. IP levels decreased in both groups (p < 0.05 at all timepoints). Although
IP release after breakfast did not differ between treatments, GLA induced a greater reduction in IP release after lunch (p = 0.08) and dinner
(p = 0.04). Total plasma insulin levels did not differ between groups.
Conclusions: Adding basal insulin to metformin reduces postprandial β-cell load. While GLA and NPH had comparable effects at breakfast,
GLA reduces β-cell stress more effectively at dinner, and with a trend at lunch, most probably because of its longer lasting pharmacodynamic
proﬁle.
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Introduction
Increasing β-cell stress with subsequent failure to release suf-
ﬁcient amounts of biologically active insulin is thought to
precede the deterioration of blood glucose control in individ-
uals with type 2 diabetes treated with oral agents [1,2]. Type
2 diabetes is classically monitored by measurement of labora-
tory markers, such as HbA1c, glucose, lipids, body mass index
and blood pressure. In addition to these traditional laboratory
markers, the measurement of intact proinsulin (IP) levels may
provide pursuing information with regard to β-cell function
and disease stage [3,4].
In addition to the much weaker glucose-lowering activity,
the increasing IP levels have been reported to be associ-
ated with a substantial increase in cardiovascular risk and
are now considered to be an independent cardiovascular
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risk marker in subjects, with and without disturbed glucose
metabolism [5–7]. In individuals with type 2 diabetes, the
increasing insulin requirements, owing to insulin resistance or
excess β-cell stimulation by sulfonylurea, result in β-cell
overload with impaired processing of IP into insulin and
C-peptide [8,9]. On the contrary,recent studies have indicated
that the early introduction of insulin treatment, even at low
doses that are insufﬁcient to restore blood glucose control can
reduce β-cell stress, improve endogenous insulin processing
and mightcontribute to an improvement in the overallcardio-
vascular risk proﬁle by reducing circulating IP levels [10–12].
In individuals with type 2 diabetes, a combination of oral
antidiabetic drugs (OAD) and basal insulin is commonly
initiated after OAD treatment has failed to achieve sufﬁcient
metabolic control. In these subjects, basal insulin is usually
given in the evening to suppress hepatic gluconeogenesis
overnight, while OADs are continued to provide sufﬁcient
blood glucose control during the day. Recent studies
comparing the long-acting insulin analogue glargine (GLA)
vs. NPH insulin in combination with metformin revealed the
advantages of insulin GLA, owing to its ﬂat and long-lasting
pharmacodynamicproﬁleinpatientswithtype2diabetes [13].original article DIABETES, OBESITY AND METABOLISM
The goal of the recent study was to investigate the effect of
basal insulin treatment,by adding insulin GLAor NPH insulin
to metformin, on postprandial β- c e l lf u n c t i o ni np a t i e n t s
with type 2 diabetes using a combination of metformin and
sulfonylurea.
Research Design and Methods
Thirtyinsulin-naivesubjectswithtype2diabetestreatedwitha
combination of metformin and sulfonylurea were randomized
to receive treatment with insulin GLA or NPH insulin at
bedtime along with 1000 mg metformin twice daily. The doses
of metformin and sulfonylurea were to be stable over the last 3
monthsbeforeinclusioninthestudy.Furtherinclusioncriteria
for study participation were an HbA1c level between 6.5 and
8.5%, and an intact fasting proinsulin level between 7 and
20 pmol/l.Subjects were excluded iftheyhad been treatedwith
insulin,peroxisomeproliferator-activatedreceptor-γ agonists,
glinides or glucosidase inhibitors within the last 4 weeks prior
to the screening visit. All other concomitant treatments were
keptstableduringthestudy.Aftertheinitiationofbasalinsulin
therapy, both insulin treatments were titrated to reach a target
fasting glucose level of 100 mg/dl (5.6 mmol/l).
Atbaseline(beforeinsulintreatment)and3monthsafterthe
initiationofinsulintreatment,thesubjectsvisitedthestudysite
in the morning after an 8-h overnight fast for a test meal day
consisting of three standardized meals. For this test meal day,
the subjects were hospitalized in a comfortable environment
and an intravenous cannula for blood sampling was placed
intoalargeantecubitalorforearmvein.Thesubjectsreceiveda
standardized breakfast at 08:00 hours (434 kcal, 26.7 g protein,
15 g fat, 48 g carbohydrates), a standardized lunch at 12:00
hours (642 kcal, 48 g protein, 25 g fat, 53 g carbohydrates) and
a standardized dinner at 18:00 hours (427 kcal, 18 g protein,
23 g fat, 55 g carbohydrates). Blood samples were collected
before the test meals and 60 and 120 min after food intake to
measure plasma glucose, insulin and IP levels.
ThestudywasconductedinaccordancewiththeDeclaration
of Helsinki and was approved by the local ethical committee.
All subjects gave a written, informed consent.
Laboratory Analysis
All laboratory measurements were analysed at the Institute
for Clinical Research and Development (ikfe GmbH, Mainz,
Germany). Blood samples were centrifuged and maintained
at −20
◦C until analysis. Plasma glucose concentrations were
determined by the glucose dehydrogenase method (Super GL,
RLT, M¨ ohnesee-Delecke, Germany). Insulin was measured
by a chemiluminescence assay (Invitron, Monmouth, UK),
which shows a high cross-reactivity with insulin GLA and
NPH Insulin. Therefore, the plasma insulin levels given in
the study represent the total insulin plasma level comprising
endogenous and exogenous insulin. Intact proinsulin was
measured using an enzyme-linked immunosorbent assay
(LincoResearch, St Charles, MO, USA) and HbA1c was
determined by high-performance liquid chromatography
(Menarini Diagnostics, Neuss, Germany).
Safety
Adverse events experienced by subjects during the study were
documented by the investigator at each visit.
Subjects Sample Size Considerations and Statistical
Analysis
Noclinicalinformationwasavailablefortheprimaryendpoint:
the effects of basal insulin supplementation on postprandial IP
secretion. Therefore, this study was designed as a pilot study,
without conﬁrmatory sample size consideration. The number
of participating subjects was estimated based on a previous
study investigating the effect of low-dose prandial insulin
supplementation on postprandial IP levels [12]. Enrolment of
30subjectswasconsideredappropriatetoobtaindataofatleast
10evaluablesubjectsper treatmentarmforthefullanalysisset.
Results are presented using descriptive summary statistics.
Allmeasurementsarepresentedasmeans±standarddeviation
(SD). For the postprandial time course of IP levels, the
area under the curve (AUC) was calculated according to
the trapezoidal rule. Statistical comparison between baseline
and at 3 months of insulin treatment, and between the two
treatment groups were performed using the Student’s t-test
(paired and unpaired as appropriate). A two-tailed p < 0.05
was considered statistically signiﬁcant.
Results
Thirty subjects were randomized (15 individuals in each study
arm). One subject in the NPH insulin group terminated the
studybywithdrawinginformedconsentanddidnotreceiveany
follow-up investigation. One subject in the insulin GLA group
was excluded owing to abnormal IP levels. In total, 28 subjects
(14 subjects in each group) were included in the per-protocol
analysis. Baseline demographic data and clinical characteristics
o ft h et w og r o u p sa r ep r e s e n t e di nT a b l e1 .




As shown in Table 1, HbA1c at the start of the study
was comparable between the two groups. A slight, but
non-signiﬁcant reduction in HbA1c was observed with both
treatments. At the end of the study, the HbA1c levels were
comparable between both treatment groups (insulin GLA: 6.9







Age (years) 66.9 ± 6.2 58.0 ± 8.5
Body mass index (kg/m2) 30.0 ± 3.7 31.5 ± 4.9
Duration of diabetes (years) 11.6 ± 7.5 8.6 ± 4.7
HbA1c (%) 7.1 ± 0.6 7.1 ± 0.4
GLA, glargine.
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Table 2. Blood glucose, insulin and intact proinsulin levels at baseline and 3 months after treatment with insulin GLA or NPH insulin.
Breakfast Lunch Dinner
0  60  120  0  60  120  0  60  120 
Glucose
(mg/dl)
NPH Baseline 156 ± 34 217 ± 44 204 ± 41 141 ± 34 158 ± 41 140 ± 32 100 ± 16 145 ± 33 147 ± 37
3 months 119 ± 29∗ 197 ± 28 183 ± 38 136 ± 38 163 ± 36 146 ± 28 108 ± 15 156 ± 21 154 ± 21
GLA Baseline 158 ± 19 233 ± 27 211 ± 29 131 ± 28 142 ± 26 131 ± 20 102 ± 16 147 ± 18 148 ± 19
3 months 121 ± 23∗ 200 ± 29 181 ± 28∗ 117 ± 24 160 ± 23 151 ± 23 108 ± 19 159 ± 21 158 ± 26
Insulin
(mU/l)
NPH Baseline 18.6 ± 11.3 56.2 ± 22.2 64.0 ± 25.5 39.6 ± 20.7 52.3 ± 22.5 46.6 ± 17.6 24.0 ± 16.9 35.8 ± 19.1 39.5 ± 22.3
3 months 20.0 ± 9.6 46.8 ± 20.7∗ 51.6 ± 27.5∗ 33.0 ± 16.7 42.5 ± 15.6∗ 33.2 ± 13.7∗ 17.6 ± 9.3∗ 28.9 ± 11.9∗ 29.0 ± 10.8∗
GLA Baseline 14.7 ± 8.3 55.5 ± 27.7 66.7 ± 43.1 42.4 ± 23.2 44.3 ± 21.2 38.8 ± 30.4 17.5 ± 8.8 28.0 ± 13.1 31.2 ± 15.2
3 months 19.4 ± 7.8∗ 44.9 ± 16.7 49.8 ± 24.8 24.6 ± 11.1∗ 36.9 ± 15.7 31.5 ± 13.7 16.2 ± 6.2 25.7 ± 9.3 26.7 ± 8.9
Proinsulin
(pmol/l)
NPH Baseline 20.5 ± 12.7 33.3 ± 20.5 48.3 ± 27.3 47.6 ± 27.4 54.4 ± 31.4 57.5 ± 33.4 38.5 ± 24.7 41.1 ± 22.8 45.2 ± 26.9
3m o n t h s 7 . 2± 6.3∗ 13.5 ± 9.5∗ 23.1 ± 13.0∗ 22.3 ± 13.7∗ 25.5 ± 14.7∗ 24.4 ± 14.2∗ 15.0 ± 11.4∗ 17.8 ± 12.0∗ 20.2 ± 12.5∗
GLA Baseline 16.5 ± 6.1 27.1 ± 7.5 44.9 ± 15.6 48.9 ± 12.9 48.6 ± 14.7 48.0 ± 16.6 29.7 ± 10.4 31.4 ± 11.0 36.4 ± 11.9
3m o n t h s 5 . 7± 2.8∗ 12.8 ± 5.8∗ 23.1 ± 13.0∗ 17.7 ± 7.9∗ 20.1 ± 9.1∗ 20.7 ± 6.7 10.6 ± 5.3∗ 12.5 ± 5.7∗ 14.5 ± 5.9∗
Mean ± standard deviation. GLA, glargine.
∗p < 0.05 at 3 months vs. baseline.
± 0.6%; NPH insulin: 6.8 ± 0.7%). Insulin doses at 3 months
were comparable with both treatment regimens (insulin GLA:
23.6 ± 13.4 IU; NPH insulin: 23.3 ± 12.7 IU; p = NS). The
postprandial plasma glucose, insulin and IP levels recorded
during the test meal days at baseline and after 3 months of
insulin treatment are presented in Table 2.
A signiﬁcant reduction in fasting blood glucose levels from
baseline to endpoint was observed for both insulin treatments,
butnoconsistentchangeinthetimecourseofpostprandialglu-
coselevelswasobservedduringthestudyperiod.Fastingblood
insulin concentrations increased signiﬁcantly after adding
insulin GLA, but not with NPH insulin. No other consistent
difference in the time course of total (endogenous and exoge-
nous) blood insulin concentrations from baseline to endpoint
or between the two basal insulin treatments were observed.
As shown in Table 2, adding once-daily basal insulin to
metformin resulted in a remarkable decrease in fasting and
postprandial IP levels at all test meals. Figure 1 shows the AUC
forpostprandialIPlevelsat1and2 hafterbreakfast,lunchand
dinner.
While the total release of IP after breakfast was comparable
between the two insulin treatments, the postprandial release
of IP tend to be lower after lunch, and was signiﬁcantly lower
after dinner with insulin GLA when compared with NPH.
Overall, 12 individuals (six people in each treatment group)
reported a total of 16 adverse events (6 and 10 events in
the insulin GLA and NPH insulin group, respectively). The
most frequent type of adverse events in the NPH insulin
group was musculoskeletal and connective tissue disorders
(three patients reporting four events) and in the insulin GLA
group was infections (two patients reporting one event each).
Hypoglycaemiawas reported by two patients (one event each),
both occurring in the NPH insulin arm. On the contrary,
the only adverse event that was considered serious (a case of
Meniere’s disease) occurred in the insulin GLA group.
Conclusions
In individuals with type 2 diabetes, OAD treatment over time
is often followed by a deterioration in β-cell function, as
indicated by a sustained loss of blood glucose control [1,2].
Early β-cell dysfunction may have important physiological
implications and may serve as a target for novel treatment
strategies for diabetes mellitus [14]. Even before β-cell failure
becomes apparent with a clinically detectable deterioration
in metabolic control, there is a marked increase in release
of IP, which was reported to be an early marker for β-cell
dysfunction [3,15,16]. Furthermore, stimulation of the β cell
by sulfonylureas might impair the conversion rate from IP to
insulin and C-peptide [8,9]. On the contrary, the initiation of
insulin in individuals with type 2 diabetes, even if it is not
titrated to reduce blood glucose levels, was found to reduce
β-cell stress and improve the conversion rate of IP [11,12].
Once OADs are unable to maintain glycaemic control, insulin
treatment in type 2 diabetes is often initiated by basal insulin
supplementation in the evening, while maintaining OADs
duringtheday.Themainﬁndingofourstudyisthatinsubjects
with inadequate control with sulfonylurea and metformin
treatment, the initiation of basal insulin treatment not only
offers a reduction in fasting glucose levels but also improves
β-cell function during the day. Although a reduction in
postprandial β-cell stress was observed in our study, there
was no signiﬁcant improvement in postprandial blood glucose
levels after breakfast, lunch and dinner. Therefore, this ﬁnding
suggests that the initiation of insulin supplementation in
individuals with type 2 diabetes might evolve β-cell protective
effects which go beyond the regulation of blood glucose.
In addition to its use as a marker forβ-cell damage, elevated
IP levels were shown to stimulate adipocytes and decrease
circulatingadiponectinlevels.Intactproinsulinhasbeenshown
to increase plasminogen activator inhibitor-1 levels, which is
associatedtoanincreaseincarotidintimamediathickness [17].
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Figure 1. Area under the curve (AUC) for 1- and 2-hour postprandial
intact proinsulin levels after 3 months of treatment with adding evening
insulin glargine vs. NPH insulin to metformin 1000 mg twice daily at
breakfast (A), lunch (B), dinner (C) (white: NPH Insulin, black: Insulin
Glargine).
In addition, elevated IP levels have been shown to predict
coronary atherosclerosis [18] and the risk of cardiovascular
events in subjects with and without diabetes [5,6,19,20].
Furthermore, we recently reported a postprandial increase in
IPlevels in non-diabeticsubjects with increased cardiovascular
risk [7].Inaclinicalstudy,proinsulinadministrationforatleast
oneyearwasassociatedwithanincreasedrateofcardiovascular
events [21]. Therefore, our ﬁndings of a marked overall
decreaseinfastingandpostprandialIPlevelsaftertheinitiation
of basal insulin treatment might have important implications
not only for metabolic control, but also for cardiovascular risk
reduction in individuals with type 2 diabetes.
Insulin GLA is a long-acting human insulin analogue with
a longer time–action proﬁle and no pronounced peak of
action when compared with NPH insulin [22]. In a recent
study, treatment with insulin GLA in combination with OADs
achieved better postprandial metabolic control when com-
pared with NPH insulin in combination with OADs [13]. In
our study population, no signiﬁcant differences in glucose
control were observed between the two insulin formulations.
On the contrary, treatment with insulin GLA in combination
withmetforminrevealedamorepronouncedreductioninpost-
prandial release of IP after lunch and dinner when compared
with NPH insulin. Owing to the shorter time–action proﬁle of
NPH insulin, the rate of insulin release from the subcutaneous
tissue depot is more rapid, which exhausts the supply more
quickly and, thus, requires earlier endogenous insulin release.
The greater demand on β cell will become evident, particularly
after a meal, when the requirements for insulin are high. In
individuals with type 2 diabetes who have barely compensated
β-cell function, this will lead to a greater release of IP from the
exhausted β cells [23–25]. Despite comparable glucose con-
trol, the prolonged pharmacodynamic proﬁle of insulin GLA
results in stronger β-cell protection, lasting over 24 h.
The comparable total plasma insulin levels found in both
treatmentgroupsindicatethat,inNPHinsulin-treatedsubjects,
enhanced endogenous insulin release was able to compensate
for the shorter time–action proﬁle of NPH insulin, thereby
keeping blood glucose levels comparable between the study
groups.Nevertheless,thegreaterdemandontheβ cellsinNPH
insulin-treated subjects will be followed by an increase in the
release of IP, particularly after meals, as observed in our study.
A potential limitation of our ﬁndings is that this was an
exploratory pilot study to evaluate the protective effects on
the β cell by initiating basal insulin therapy with metformin
in individuals with type 2 diabetes, pretreated with OADs
(sulfonylureaincombinationwithmetformin).Furtherstudies
are needed to investigate if the effect of basal insulin
supplementation will translate into longer β-cell survival or
a reduction in cardiovascular risk. In addition, our study only
compared once-daily application of insulin GLA, with once-
daily injection of NPH insulin. Most probably, NPH insulin
administeredtwicedailywillresultinpostprandialIPlevelsthat
morecloselymatchthoseachievedwithonce-dailyinsulinGLA.
In conclusion, the initiation of basal insulin in combination
with metformin results in an overall improvement of β-
cell function, as indicated by a reduction in the fasting and
postprandial release of IP from the β cells. Because of the
protracted pharmacokinetic proﬁle of insulin GLA compared
with NPH insulin, treatment with insulin GLA may offer
moreprolongedβ-cellpreservationwhencomparedwithNPH
insulin applied once daily.
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